Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001062993-25-016345
Filing Date
2025-10-29
Accepted
2025-10-28 20:17:06
Documents
12
Period of Report
2024-02-06

Document Format Files

Seq Description Document Type Size
1 FORM 6-K form6k.htm 6-K 15149
2 EXHIBIT 99.1 exhibit99-1.htm EX-99.1 7763
3 EXHIBIT 99.2 exhibit99-2.htm EX-99.2 7042
4 EXHIBIT 99.3 exhibit99-3.htm EX-99.3 5589
5 EXHIBIT 99.4 exhibit99-4.htm EX-99.4 22402
6 EXHIBIT 99.5 exhibit99-5.htm EX-99.5 9263
7 EXHIBIT 99.6 exhibit99-6.htm EX-99.6 25304
8 EXHIBIT 99.7 exhibit99-7.htm EX-99.7 21472
9 EXHIBIT 99.8 exhibit99-8.htm EX-99.8 6179
10 EXHIBIT 99.9 exhibit99-9.htm EX-99.9 7443
11 EXHIBIT 99.10 exhibit99-10.htm EX-99.10 16628
12 EXHIBIT 99.11 exhibit99-11.htm EX-99.11 8811
  Complete submission text file 0001062993-25-016345.txt   154278
Mailing Address 55 UNIVERSITY AVENUE, SUITE 1003 TORONTO Ontario, Canada M5J 2H7
Business Address 55 UNIVERSITY AVENUE, SUITE 1003 TORONTO Ontario, Canada M5J 2H7 (416) 854-8884
Quantum Biopharma Ltd. (Filer) CIK: 0001771885 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39152 | Film No.: 251426463
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)